Topic: Health

A new daily pill called orforglipron has been found to be more effective for weight loss and blood sugar control than its current counterparts. The trial involved 1,698 adults with type 2 diabetes across six countries. Orforglipron was able to reduce HbA1c levels by an average of 1.71-1.91%, compared to oral semaglutide's reduction of 1.47%.

A new type of daily pill has been proven more effective for weight loss and blood sugar control than its currently available counterparts. The drug, known as orforglipron, could be a game-changer in the rapidly expanding oral weight-loss drug market.

The advent of injectable weight-loss drugs like semaglutide, marketed under brand names Wegovy (for weight loss) and Ozempic (for type 2 diabetes), marked a distinct shift in the weight-loss drugs market when it became available just a few years ago. Semaglutide is a class of glucagon-like peptide-1 (GLP-1) medication.

These GLP-1 drugs mimic the gut hormone GLP-1, which is released soon after eating. This hormone signals fullness to the brain, slowing digestion and stimulating the release of insulin. By replicating the action of this hormone, GLP-1 drugs have proven highly effective at managing type 2 diabetes and promoting weight loss.

However, a key issue with injectable GLP-1 drugs like semaglutide is that they need to be injected into the belly, thighs or back of the arm. This can make it difficult for patients with needle phobia or who don't want to self-inject due to the inconvenience. Another logistical issue with injectable GLP-1 drugs is that they require refrigeration throughout the supply chain.

Based on current research, oral semaglutide has been found to be very effective for weight loss and blood sugar control. However, it must be taken on an empty stomach – and users must wait 30 minutes before eating or drinking. Alongside being expensive to produce, it also has poor bioavailability compared with injectable semaglutide.

But a recent phase 3 clinical trial has shown that a new type of oral weight-loss pill may have overcome these issues, making it competitive with the current oral semaglutide products on the market. The recent 52-week phase 3 trial involved 1,698 adults with type 2 diabetes across six countries.

It set out to compare current oral semaglutide products against orforglipron, which is also taken as a daily tablet. The primary measure researchers were looking for was a reduction in HbA1c levels. From a baseline average HbA1c of 8.3%, it was found that after 52 weeks, orforglipron was able to reduce this value by an average of 1.71-1.91%. In comparison, oral semaglutide only reduced HbA1c by 1.47%.

Not only did orforglipron meet the trial's goals of proving it was as effective as oral semaglutide, it proved it was superior for lowering blood sugar. The participants who took orforglipron also lost more weight – an average of 6.1kg-8.2kg, compared with 5.3kg in those taking semaglutide.

However, a key issue highlighted by the trial was one of tolerability. GLP-1 drugs can cause gastrointestinal side-effects such as nausea, vomiting, diarrhea and constipation. In this latest trial, around 59% of participants on orforglipron reported such symptoms, compared with 37-45% on semaglutide.

The reason for this difference may be the more prominent, daily peak drug concentrations with orforglipron. The consequence was that around 10% of orforglipron participants discontinued treatment due to adverse effects. Just 4-5% of those taking semaglutide discontinued treatment.

Why It Matters

This breakthrough in weight loss and blood sugar control could have a significant impact on the lives of millions of people with type 2 diabetes in India, where the disease is becoming increasingly common. It also highlights the importance of continued research into new treatments for this condition.

Key Facts

• A recent phase 3 clinical trial involving 1,698 adults with type 2 diabetes across six countries found that orforglipron was more effective than oral semaglutide in reducing HbA1c levels and promoting weight loss.
• Orforglipron reduced HbA1c levels by an average of 1.71-1.91%, compared to oral semaglutide's reduction of 1.47%.
• The participants who took orforglipron also lost more weight – an average of 6.1kg-8.2kg, compared with 5.3kg in those taking semaglutide.
• A key issue highlighted by the trial was one of tolerability, with around 59% of participants on orforglipron reporting gastrointestinal side-effects compared to 37-45% on semaglutide.
• The trial's results show that orforglipron can be considered a game-changer in the rapidly expanding oral weight-loss drug market.

Key Terms

GLP-1

A hormone released by the gut after eating, which signals fullness to the brain and stimulates insulin release.

HbA1c

A blood test that reflects average blood sugar levels over three months.

Implications

This breakthrough in weight loss and blood sugar control could have a significant impact on the lives of millions of people with type 2 diabetes in India, where the disease is becoming increasingly common. It also highlights the importance of continued research into new treatments for this condition.